Abstract
Cancer Biotherapy & RadiopharmaceuticalsVol. 16, No. 1 EditorialsRadioimmunotherapy of Solid Tumors: From Fairytale to RealityGregory P. Adams and Louis M. WeinerGregory P. AdamsSearch for more papers by this author and Louis M. WeinerSearch for more papers by this authorPublished Online:5 Jul 2004https://doi.org/10.1089/108497801750095925AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byRecombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas27 January 2010 | International Journal of Cancer, Vol. 127, No. 3Conformational analysis of cysteine-containing peptides and prospects of their application to 213Bi chelating in antitumor therapy26 May 2006 | Russian Journal of Bioorganic Chemistry, Vol. 32, No. 3Designing antibodies for oncologyCancer and Metastasis Reviews, Vol. 24, No. 4Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus1 January 2005 | International Journal of Cancer, Vol. 116, No. 5Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody1 January 2004 | International Journal of Cancer, Vol. 110, No. 6 Volume 16Issue 1Feb 2001 To cite this article:Gregory P. Adams and Louis M. Weiner.Radioimmunotherapy of Solid Tumors: From Fairytale to Reality.Cancer Biotherapy and Radiopharmaceuticals.Feb 2001.9-11.http://doi.org/10.1089/108497801750095925Published in Volume: 16 Issue 1: July 5, 2004PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
